In a report made public this week, the French National Authority for Health recommended NIPT if first semester screening indicated a risk between 1 in 51 and 1 in 1,000.
For the year ended March 31, the Manchester, UK-based provider of noninvasive prenatal testing reported more than £3.1 million ($4 million) in revenue.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
The company said that Illumina and Sequenom's NIPT patents are not present in the Middle East, allowing it to sell its Iona test unimpeded.
The G-BA commissioned a contractor to prepare an evidence report by early 2018 and to gather information for patients by early 2019.
The results of the Harvard-led study suggest that the immune system struggles to infiltrate and attack tumors with more aneuploidy.
The collaborators will explore the use of cell-free DNA for preimplantation genetic testing.
Going forward, Natera said it will market its Panorama NIPT assay and carrier screening test Horizon directly to physicians.
LifeCodexx's PrenaTest will be available to women in Malaysia, Singapore, Thailand, Brunei, Vietnam, the United Arab Emirates, and elsewhere in the Middle East.
A new study shows that combining size-based and count-based analysis helps determine whether a copy number aberration originates in the mother, fetus, or both.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.